Rhodiola rosea, sometimes called golden root, is a fleshy perennial that grows in cold high places — the Arctic, the Altai mountains, the Pyrenees. Russian and Scandinavian traditions used the root for centuries to push through cold, fatigue, and altitude. Modern interest centers on two compound families isolated from the root, rosavins and salidroside, and on a single Swedish extract, SHR-5, that has carried most of the clinical work. The evidence stack is thinner than ashwagandha’s but worth knowing.
What the trials show
A 2009 randomized trial gave 576 mg per day of SHR-5 or placebo to 60 adults with stress-related fatigue for 28 days. The treated group showed significant improvements on the Pines Burnout Scale and on attention measures, along with a small reduction in morning cortisol.1 The effect was modest and the trial was small, but the design was clean.
A 2007 trial tested SHR-5 at 340 and 680 mg per day against placebo in 89 adults with mild-to-moderate depression. Both active doses outperformed placebo on the Hamilton Depression Rating Scale.2 The depression literature here is small enough that this trial gets cited heavily, but it is one trial.
The earliest randomized work — a 2000 pilot study in Russian medical students during an exam period — found that a 50 mg dose of SHR-5 twice daily reduced fatigue scores and improved physical fitness markers compared with placebo.3 The doses here are well below later trials and the cohort was small, but it set the pattern of using rhodiola as an anti-fatigue intervention rather than a stimulant.
The most clinically interesting trial was a 2015 head-to-head with sertraline in 57 adults with major depression. Rhodiola underperformed the SSRI on efficacy, as expected, but produced markedly fewer side effects, and the absolute difference in remission was smaller than the difference in tolerability.4 That is a useful framing: rhodiola is not a substitute for an SSRI in clinical depression, but the trade-off is honest.
A systematic review of 11 trials noted what is true of most adaptogen literature — most studies are small, many are funded by the manufacturer, and the strongest signals are in fatigue and stress endpoints rather than disease outcomes.5
How to use it
The dosing range across the SHR-5 trials is 100 to 680 mg per day of an extract standardized to roughly 3 percent rosavins and 1 percent salidroside. Most practical protocols land at 200–400 mg per day, taken in the morning. Rhodiola can be mildly activating, so evening dosing risks disrupting sleep.
Effects tend to appear within days rather than weeks — closer to a stimulant’s timing than ashwagandha’s slow accumulation. Cycling on and off (six weeks on, two weeks off) is a common precaution, although the empirical basis for cycling is mostly traditional rather than trial-driven.
What it is not
Rhodiola is not an antidepressant in the clinical sense — the head-to-head with sertraline made that clear. It is not as well studied as ashwagandha, and the trial roster leans heavily on one extract from one manufacturer, which is a real caveat when assessing generalizability. The hepatotoxicity signal that has emerged with ashwagandha has not appeared with rhodiola, but long-term safety data beyond 12 weeks are limited.
The most defensible use is exactly the one the trials support: a low-risk tool for stress-related fatigue and mild burnout, paired with the basics of sleep, training, and a defensible caffeine schedule rather than substituted for them.